Market Newsdesk

Urban Edge Properties Reports First Quarter 2026 Results

NEW YORK–(BUSINESS WIRE)–
Urban Edge Properties (NYSE: UE) (the “Company”) today announced its results for the quarter ended March 31, 2026 and updated its outlook for full-year 2026.

“Our first quarter results reflect the continued strength and quality of our portfolio,” said Jeff Olson, Chairman and CEO. “We executed 419,000 sf of leasing transactions in the quarter, including 84,000 sf of new leases at a cash spread of 52%, and 335,000 sf of renewals, achieving a blended cash spread of 15%. We acquired The Village at Bridgewater Commons in Bridgewater, New Jersey for $54 million, advancing our external growth plans. We have also raised the low end of our FFO as Adjusted guidance from a range of $1.47 to $1.52 per diluted share to $1.48 to $1.52 per diluted share.”

“As we look ahead, our leasing pipeline remains robust, our balance sheet is well-positioned, and we believe the fundamentals driving our business – including the ongoing demand for high-quality retail space and supply constraints in our markets – will translate into sustained long-term growth,” he concluded.

Financial Results⁽¹⁾⁽²⁾

(in thousands, except per share amounts)		1Q26				1Q25
Net income attributable to common shareholders		$	22,645		$	8,198
Net income per diluted share			0.18			0.07
Funds from Operations (“FFO”)			55,657			45,458
FFO per diluted share			0.42			0.35
FFO as Adjusted			47,569			45,921
FFO as Adjusted per diluted share			0.36			0.35

The increases in net income, FFO and FFO as Adjusted for the three months ended March 31, 2026 were driven by rent commencements on new leases, higher net recovery revenue, growth from accretive capital recycling and lower interest and debt expense. Net income and FFO for the three months ended March 31, 2026 also benefited from $8.4 million, or $0.06 per diluted share, of non-recurring reimbursements received during the quarter pertaining to previously incurred environmental remediation costs.

Same-Property Operating Results Compared to the Prior Year Period⁽¹⁾⁽³⁾

		1Q26
Same-property Net Operating Income (“NOI”) growth		2.4	%
Same-property NOI growth, including properties in redevelopment		2.8	%

Increases in same-property NOI metrics for the three months ended March 31, 2026 were driven by rent commencements on new leases from our signed but not open pipeline and higher net recovery revenue, partially offset by higher levels of uncollected rents.

Leasing and Occupancy Results⁽¹⁾

• The Company reported same-property portfolio leased occupancy of 96.4%, a decrease of 30 basis points compared to March 31, 2025 and December 31, 2025.

• Consolidated portfolio leased occupancy was 96.4%, flat compared to March 31, 2025 and a decrease of 30 basis points compared to December 31, 2025.

• Retail shop leased occupancy was 92.4%, flat compared to March 31, 2025 and a decrease of 20 basis points compared to December 31, 2025.

• The Company executed 45 new leases, renewals and options totaling 419,000 sf during the quarter. New leases totaled 84,000 sf, of which 59,000 sf was on a same-space basis and generated an average cash spread of 51.6%. New leases, renewals and options totaled 394,000 sf on a same-space basis and generated an average cash spread of 14.6%.

• As of March 31, 2026, signed leases that have not yet rent commenced are expected to generate an additional $21.7 million of future annual gross rent, representing approximately 7% of current annualized NOI. Approximately $3.3 million of this amount is expected to be recognized in the remainder of 2026.

Acquisition Activity

On March 30, 2026, the Company acquired The Village at Bridgewater Commons for a gross purchase price of $54.3 million, reflecting a 7.7% capitalization rate. The 92,000 sf shopping center is located in Bridgewater, NJ along a highly trafficked and affluent retail corridor with a 5-mile annual average household income of $183,000. The center features a freestanding medical building for Summit Health as well as several high-quality quick-service restaurants including Chipotle, Shake Shack, Cava and Starbucks.

Financing Activity

On January 22, 2026, the Company entered into $950 million of unsecured credit facilities, expanding its borrowing capacity by $150 million. The unsecured credit facilities are comprised of an unsecured line of credit and two delayed-draw term loans aggregating $250 million.

The Company’s existing revolving credit agreement was amended and restated to reduce the unsecured line of credit by $100 million to $700 million and extend the maturity date to June 2030 with two six-month extension options. The term loans are $125 million each consisting of a 5-year maturity and a 7-year maturity, both of which have a delayed-draw feature through January 22, 2027. Based on the Company’s current leverage ratio, borrowings under the unsecured line of credit, 5-year term loan and 7-year term loan bear interest at SOFR plus 1.00%, SOFR plus 1.15% and SOFR plus 1.50%, respectively.

On March 18, 2026, the Company obtained a $62.5 million, 7-year non-recourse mortgage secured by Plaza at Woodbridge with a swapped fixed interest rate of 5.0%.

As of March 31, 2026, the Company had $30 million outstanding under its unsecured line of credit and no amounts drawn on either of the 5-year or 7-year term loans.

Development and Redevelopment

During the quarter, the Company stabilized four redevelopment projects totaling $6.8 million with new rent commencements from Lidl and Boot Barn at Totowa Commons, Ross Dress for Less at Plaza at Woodbridge, Texas Roadhouse at Outlets at Montehiedra, and Big Blue Swim School at Plaza at Cherry Hill.

As of March 31, 2026, the Company has $157.3 million of active development and redevelopment projects underway, with estimated remaining costs to complete of $66.8 million. The active development and redevelopment projects are expected to generate an approximate 13% yield.

Balance Sheet and Liquidity^(1)(4)(5)

Balance sheet highlights as of March 31, 2026 include:

• Total liquidity of approximately $968 million, consisting of $76 million of cash on hand and $892 million available under the Company’s $950 million of unsecured credit facilities, including undrawn letters of credit.

• Mortgages payable of $1.68 billion, with a weighted average term to maturity of 3.6 years, all of which are fixed rate or hedged.

• $30 million drawn on our $700 million unsecured line of credit that matures on June 28, 2030, with two six-month extension options.

• No outstanding balance on our $250 million of delayed-draw term loans.

• Total market capitalization of approximately $4.37 billion, comprised of 133.3 million fully-diluted common shares valued at $2.66 billion and $1.71 billion of debt.

• Net debt to total market capitalization of 37%.

2026 Outlook

The Company has updated its 2026 full-year guidance ranges for net income and FFO and raised the low end of its guidance range by $0.01 per diluted share for FFO as Adjusted, estimating net income of $0.56 to $0.60 per diluted share, FFO of $1.54 to $1.58 per diluted share and FFO as Adjusted of $1.48 to $1.52 per diluted share. A reconciliation of the range of estimated earnings, FFO and FFO as Adjusted, the assumptions used in our guidance, and a reconciliation bridging 2025 FFO per diluted share to the 2026 estimates can be found on pages 4 and 5 of this release.

Earnings Conference Call Information

The Company will host an earnings conference call and audio webcast on April 29, 2026 at 8:30 AM ET. All interested parties can access the earnings call by dialing 1-877-407-9716 (Toll Free) or 1-201-493-6779 (Toll/International) using conference ID 13759141. The call will also be webcast and available in listen-only mode on the investors page of our website: www.uedge.com. A replay will be available at the webcast link on the investors page for one year following the conclusion of the call. A telephonic replay of the call will also be available starting April 29, 2026 at 11:30 AM ET through May 13, 2026 at 11:59 PM ET by dialing 1-844-512-2921 (Toll Free) or 1-412-317-6671 (Toll/International) using conference ID 13759141.

(1)	Refer to “Non-GAAP Financial Measures” on page 6 and “Operating Metrics” on page 7 for definitions and additional details. Reported consolidated occupancy excludes the impact of Sunrise Mall. Including Sunrise Mall, consolidated portfolio leased occupancy was 89.9% at March 31, 2026.
(2)	Refer to page 11 for a reconciliation of net income to FFO and FFO as Adjusted for the three months ended March 31, 2026.
(3)	Refer to page 12 for a reconciliation of net income to NOI and Same-Property NOI for the three months ended March 31, 2026.
(4)	Net debt as of March 31, 2026 is calculated as total consolidated debt of $1.7 billion less total cash and cash equivalents, including restricted cash, of $76 million.
(5)	Availability under our unsecured credit facilities is net of letters of credit issued under the unsecured line of credit. The Company obtained seven letters of credit aggregating $27.9 million which have reduced the available balance commensurate with their face values but remain undrawn and no separate liability has been recorded.

2026 Earnings Guidance

The Company has updated its 2026 full-year guidance ranges for net income and FFO and raised the low end of its guidance range by $0.01 per diluted share for FFO as Adjusted, estimating net income of $0.56 to $0.60 per diluted share, FFO of $1.54 to $1.58 per diluted share and FFO as Adjusted of $1.48 to $1.52 per diluted share. Below is a summary of the Company’s 2026 outlook, assumptions used in its forecasting, and a reconciliation of the range of estimated earnings, FFO, and FFO as Adjusted per diluted share.

		Previous Guidance		Revised Guidance
Net income per diluted share		$0.49 – $0.54		$0.56 – $0.60
Net income attributable to common shareholders per diluted share		$0.47 – $0.52		$0.54 – $0.58
FFO per diluted share		$1.47 – $1.52		$1.54 – $1.58
FFO as Adjusted per diluted share		$1.47 – $1.52		$1.48 – $1.52

The Company’s revised 2026 full-year outlook is based on the following assumptions:

• Same-property NOI growth, including properties in redevelopment, of 3.00% to 3.75%, reflecting an increase on the low end from our previous assumption of 2.75% to 3.75%.

• Recurring G&A expenses ranging from $34.5 million to $36.5 million, unchanged from our previous assumption.

• Interest and debt expense ranging from $78.0 million to $79.0 million, reflecting a decrease from our previous assumption of $78.9 million to $80.9 million.

• Acquisitions of $54 million, reflecting activity completed year-to-date, and dispositions of $60 million to $65 million.

• Excludes items that impact FFO comparability, including gains and/or losses on extinguishment of debt, transaction, severance, litigation, and other one-time items outside of the ordinary course of business.

	Guidance 2026E								Per Diluted Share(1)
(in thousands, except per share amounts)	Low				High				Low				High
Net income	$	73,600			$	78,900			$	0.56			$	0.60
Less net (income) loss attributable to noncontrolling interests in:
Operating partnership		(3,800	)			(4,000	)			(0.03	)			(0.03	)
Consolidated subsidiaries		900				900				0.01				0.01
Net income attributable to common shareholders		70,700				75,800				0.54				0.58
Adjustments:
Rental property depreciation and amortization		127,200				127,200				0.97				0.97
Limited partnership interests in operating partnership		3,800				4,000				0.03				0.03
FFO Applicable to diluted common shareholders		201,700				207,000				1.54				1.58
Adjustments to FFO:
Transaction, severance, litigation expenses and other, net		(7,900	)			(7,900	)			(0.06	)			(0.06	)
Loss on extinguishment of debt		200				200				—				—
FFO as Adjusted applicable to diluted common shareholders	$	194,000			$	199,300			$	1.48			$	1.52
(1) Amounts may not foot due to rounding.

The following table is a reconciliation bridging 2025 FFO per diluted share to the Company’s estimated 2026 FFO per diluted share:

	Per Diluted Share(1)
	Low				High
2025 FFO applicable to diluted common shareholders	$	1.43			$	1.43
2025 Items impacting FFO comparability(2)		0.01				0.01
2026 Items impacting FFO comparability(2)		0.06				0.06
Same-property NOI growth, including redevelopment		0.06				0.08
Acquisitions net of dispositions NOI growth		0.01				0.01
Recurring general and administrative		(0.01	)			—
Straight-line rent and non-cash items		(0.01	)			—
2026 FFO applicable to diluted common shareholders	$	1.54			$	1.58

(1)	Amounts may not foot due to rounding.
(2)	Includes adjustments to FFO for fiscal year 2025 and expected adjustments for fiscal year 2026 which impact comparability. See “Reconciliation of net income to FFO and FFO as Adjusted” on page 11 for actual adjustments year-to-date and our fourth quarter 2025 Supplemental Disclosure Package for 2025 adjustments.

The Company is providing a projection of anticipated net income solely to satisfy the disclosure requirements of the Securities and Exchange Commission (“SEC”). The Company’s projections are based on management’s current beliefs and assumptions about the Company’s business, and the industry and the markets in which it operates; there are known and unknown risks and uncertainties associated with these projections. There can be no assurance that actual results will not differ from the guidance set forth above. The Company assumes no obligation to update publicly any forward-looking statements, including its 2026 earnings guidance, whether as a result of new information, future events or otherwise. Please refer to the “Forward-Looking Statements” disclosures on page 8 of this document and “Risk Factors” disclosed in the Company’s annual and quarterly reports filed with the SEC for more information.

Non-GAAP Financial Measures

The Company uses certain non-GAAP performance measures, in addition to the primary GAAP presentations, as we believe these measures improve the understanding of the Company’s operational results. We continually evaluate the usefulness, relevance, limitations, and calculation of our reported non-GAAP performance measures to determine how best to provide relevant information to the investing public, and thus such reported measures are subject to change. The Company’s non-GAAP performance measures have limitations as they do not include all items of income and expense that affect operations, and accordingly, should always be considered as supplemental financial results. Additionally, the Company’s computation of non-GAAP metrics may not be comparable to similarly titled non-GAAP metrics reported by other real estate investment trusts (“REITs”) or real estate companies that define these metrics differently and, as a result, it is important to understand the manner in which the Company defines and calculates each of its non-GAAP metrics. The following non-GAAP measures are commonly used by the Company and investing public to understand and evaluate our operating results and performance:

• FFO: The Company believes FFO is a useful, supplemental measure of its operating performance that is a recognized metric used extensively by the real estate industry and, in particular REITs. FFO, as defined by the National Association of Real Estate Investment Trusts (“Nareit”) and the Company, is net income (computed in accordance with GAAP), excluding gains (or losses) from sales of depreciable real estate and land when connected to the main business of a REIT, impairments on depreciable real estate or land related to a REIT’s main business, earnings from consolidated partially owned entities and rental property depreciation and amortization expense. The Company believes that financial analysts, investors and shareholders are better served by the presentation of comparable period operating results generated from FFO primarily because it excludes the assumption that the value of real estate assets diminishes predictably. FFO does not represent cash flows from operating activities in accordance with GAAP, should not be considered an alternative to net income as an indication of our performance, and is not indicative of cash flow as a measure of liquidity or our ability to make cash distributions.

• FFO as Adjusted: The Company provides disclosure of FFO as Adjusted because it believes it is a useful supplemental measure of its core operating performance that facilitates comparability of historical financial periods. FFO as Adjusted is calculated by making certain adjustments to FFO to account for items the Company does not believe are representative of ongoing core operating results, including non-comparable revenues and expenses. The Company’s method of calculating FFO as Adjusted may be different from methods used by other REITs and, accordingly, may not be comparable to such other REITs.

• NOI: The Company uses NOI internally to make investment and capital allocation decisions and to compare the unlevered performance of our properties to our peers. The Company believes NOI is useful to investors as a performance measure because, when compared across periods, NOI reflects the impact on operations from trends in occupancy rates, rental rates, operating costs and acquisition and disposition activity on an unleveraged basis, providing perspective not immediately apparent from net income. The Company calculates NOI using net income as defined by GAAP reflecting only those income and expense items that are incurred at the property level and through the Company’s captive insurance program, adjusted for non-cash rental income and expense, impairments on depreciable real estate or land, and income or expenses that we do not believe are representative of ongoing operating results, if any. In addition, the Company uses NOI margin, calculated as NOI divided by total property revenue, which the Company believes is useful to investors for similar reasons.

• Same-property NOI: The Company provides disclosure of NOI on a same-property basis, which includes the results of properties that were owned and operated for the entirety of the reporting periods being compared, which total 66 properties for the three months ended March 31, 2026 and 2025. Information provided on a same-property basis excludes properties under development, redevelopment or that involve anchor repositioning where a substantial portion of the gross leasable area (“GLA”) is taken out of service and also excludes properties acquired, sold, or that are in the foreclosure process during the periods being compared, and results of our captive insurance program. As such, same-property NOI assists in eliminating disparities in net income due to the development, redevelopment, acquisition, disposition, or foreclosure of properties and results of our captive insurance program during the periods presented, and thus provides a more consistent performance measure for the comparison of the operating performance of the Company’s properties. While there is judgment surrounding changes in designations, a property is removed from the same-property pool when it is designated as a redevelopment property because it is undergoing significant renovation or retenanting pursuant to a formal plan that is expected to have a significant impact on its operating income. A development or redevelopment property is moved back to the same-property pool once a substantial portion of the NOI growth expected from the development or redevelopment is reflected in both the current and comparable prior year period, generally one year after at least 80% of the expected NOI from the project is realized on a cash basis. Acquisitions are moved into the same-property pool once we have owned the property for the entirety of the comparable periods and the property is not under significant development or redevelopment. The Company has also provided disclosure of NOI on a same-property basis adjusted to include redevelopment properties. Same-property NOI may include other adjustments as detailed in the Reconciliation of Net Income to NOI and same-property NOI included in the tables accompanying this press release.

• EBITDAre and Adjusted EBITDAre: EBITDAre and Adjusted EBITDAre are supplemental, non-GAAP measures utilized by us in various financial ratios. The White Paper on EBITDAre, approved by Nareit’s Board of Governors in September 2017, defines EBITDAre as net income (computed in accordance with GAAP), adjusted for interest expense, income tax (benefit) expense, depreciation and amortization, losses and gains on the disposition of depreciated property, impairment write-downs of depreciated property and investments in unconsolidated joint ventures, and adjustments to reflect the entity’s share of EBITDAre of unconsolidated joint ventures. EBITDAre and Adjusted EBITDAre are presented to assist investors in the evaluation of REITs, as a measure of the Company’s operational performance as they exclude various items that do not relate to or are not indicative of our operating performance and because they approximate key performance measures in our debt covenants. Accordingly, the Company believes that the use of EBITDAre and Adjusted EBITDAre, as opposed to income before income taxes, in various ratios provides meaningful performance measures related to the Company’s ability to meet various coverage tests for the stated periods. Adjusted EBITDAre may include other adjustments not indicative of operating results as detailed in the Reconciliation of Net Income to EBITDAre and Adjusted EBITDAre included in the tables accompanying this press release. The Company also presents the ratio of net debt (net of cash) to annualized Adjusted EBITDAre as of March 31, 2026, and net debt (net of cash) to total market capitalization, which it believes is useful to investors as a supplemental measure in evaluating the Company’s balance sheet leverage.

The Company believes net income is the most directly comparable GAAP financial measure to the non-GAAP performance measures outlined above. Reconciliations of these measures to net income have been provided in the tables accompanying this press release.

Operating Metrics

The Company presents certain operating metrics related to our properties, including occupancy, leasing activity and rental rates. Operating metrics used by the Company are useful to investors in facilitating an understanding of the operational performance for our properties.

Recovery ratios represent the percentage of operating expenses recuperated through tenant reimbursements. This metric is presented on a same-property and same-property including redevelopment basis and is calculated by dividing tenant expense reimbursements (adjusted to exclude any ancillary income) by the sum of real estate taxes and property operating expenses.

Occupancy metrics represent the percentage of occupied gross leasable area based on executed leases (including properties in development and redevelopment) and include leases signed, but for which rent has not yet commenced. Same-property portfolio leased occupancy includes properties that have been owned and operated for the entirety of the reporting periods being compared, which total 66 properties for the three months ended March 31, 2026 and 2025. Occupancy metrics presented for the Company’s same-property portfolio exclude properties under development, redevelopment or that involve anchor repositioning where a substantial portion of the gross leasable area is taken out of service and also excludes properties acquired within the past 12 months or properties sold, and properties that are in the foreclosure process during the periods being compared.

Executed new leases, renewals and exercised options are presented on a same-space basis. Same-space leases represent those leases signed on spaces for which there was a previous lease.

The Company occasionally provides disclosures by tenant categories which include anchors, shops and industrial/self-storage. Anchors and shops are further broken down by local, regional and national tenants. We define anchor tenants as those who have a leased area of >10,000 sf. Local tenants are defined as those with less than five locations. Regional tenants are those with five or more locations in a single region. National tenants are defined as those with five or more locations and that operate in two or more regions.

ADDITIONAL INFORMATION

For a copy of the Company’s supplemental disclosure package, please access the “Investors” section of our website at www.uedge.com. Our website also includes other financial information, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any amendments to those reports.

The Company uses, and intends to continue to use, the “Investors” page of its website, which can be found at www.uedge.com, as a means of disclosing material nonpublic information and of complying with its disclosure obligations under Regulation FD, including, without limitation, through the posting of investor presentations that may include material nonpublic information. Accordingly, investors should monitor the “Investors” page, in addition to following the Company’s press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, our website is not incorporated by reference into, and is not a part of, this document.

ABOUT URBAN EDGE

Urban Edge Properties is a NYSE listed real estate investment trust focused on owning, managing, acquiring, developing, and redeveloping retail real estate in urban communities, primarily in the Washington, D.C. to Boston corridor. Urban Edge owns 74 properties totaling 17.3 million square feet of gross leasable area.

FORWARD-LOOKING STATEMENTS

Certain statements contained herein constitute forward-looking statements as such term is defined in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements are not guarantees of future performance. They represent our intentions, plans, expectations and beliefs and are subject to numerous assumptions, risks and uncertainties. Our future results, financial condition, business and targeted occupancy may differ materially from those expressed in these forward-looking statements. You can identify many of these statements by words such as “approximates,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “would,” “may” or other similar expressions in this press release. Many of the factors that will determine the outcome of forward-looking statements are beyond our ability to control or predict and include, among others: (i) macroeconomic conditions, including geopolitical conditions and instability, and international trade disputes, including any related tariffs, which may lead to rising inflation, adverse impacts to supply chains, and disruption of, or lack of access to, the capital markets, as well as potential volatility in the Company’s share price; (ii) the economic, political and social impact of, and uncertainty relating to, epidemics and pandemics; (iii) the loss or bankruptcy of major tenants; (iv) the ability and willingness of the Company’s tenants to renew their leases with the Company upon expiration and the Company’s ability to re-lease its properties on the same or better terms, or at all, in the event of non-renewal or in the event the Company exercises its right to replace an existing tenant; (v) the impact of e-commerce on our tenants’ business; (vi) the Company’s success in implementing its business strategy and its ability to identify, underwrite, finance, consummate and integrate diversifying acquisitions and investments; (vii) changes in general economic conditions or economic conditions in the markets in which the Company competes, and their effect on the Company’s revenues, earnings and funding sources, and on those of its tenants; (viii) increases in the Company’s borrowing costs as a result of changes in interest rates, rising inflation, and other factors; (ix) the Company’s ability to pay down, refinance, hedge, restructure or extend its indebtedness as it becomes due and potential limitations on the Company’s ability to borrow funds under its existing credit facility as a result of covenants relating to the Company’s financial results; (x) potentially higher costs associated with the Company’s development, redevelopment and anchor repositioning projects, and the Company’s ability to lease the properties at projected rates; (xi) the Company’s liability for environmental matters; (xii) damage to the Company’s properties from catastrophic weather and other natural events, and the physical effects of climate change; (xiii) the Company’s ability and willingness to maintain its qualification as a REIT in light of economic, market, legal, tax and other considerations; (xiv) information technology security breaches; (xv) the loss of key executives; and (xvi) the accuracy of methodologies and estimates regarding our environmental, social and governance (collectively, our Corporate Responsibility or “CR”) metrics, goals and targets, tenant willingness and ability to collaborate towards reporting CR metrics and meeting CR goals and targets, and the impact of governmental regulation on our CR efforts. For further discussion of factors that could materially affect the outcome of our forward-looking statements, see “Risk Factors” in Part I, Item 1A, of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the other documents filed by the Company with the Securities and Exchange Commission (the “SEC”).

We claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 for any forward-looking statements included in this press release. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. All subsequent written and oral forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. We do not undertake any obligation to release publicly any revisions to our forward-looking statements to reflect events or circumstances occurring after the date of this press release.

URBAN EDGE PROPERTIES
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
	March 31,				December 31,
	2026				2025
ASSETS
Real estate, at cost:
Land	$	676,038			$	669,078
Buildings and improvements		2,878,759				2,835,540
Construction in progress		358,886				327,413
Furniture, fixtures and equipment		13,485				13,059
Total		3,927,168				3,845,090
Accumulated depreciation and amortization		(956,464	)			(935,548	)
Real estate, net		2,970,704				2,909,542
Operating lease right-of-use assets		57,225				58,917
Cash and cash equivalents		49,996				48,881
Restricted cash		25,870				29,984
Tenant and other receivables		33,881				26,658
Receivables arising from the straight-lining of rents		64,205				63,842
Identified intangible assets, net of accumulated amortization of $69,080 and $70,514, respectively		91,057				87,591
Deferred leasing costs, net of accumulated amortization of $22,671 and $21,982, respectively		31,193				31,220
Prepaid expenses and other assets		64,830				55,236
Total assets	$	3,388,961			$	3,311,871
LIABILITIES AND EQUITY
Liabilities:
Mortgages payable, net	$	1,665,218			$	1,606,774
Unsecured line of credit		30,000				—
Operating lease liabilities		54,710				56,329
Accounts payable, accrued expenses and other liabilities		83,799				97,397
Identified intangible liabilities, net of accumulated amortization of $62,274 and $59,668, respectively		173,780				174,899
Total liabilities		2,007,507				1,935,399
Commitments and contingencies
Shareholders’ equity:
Common shares: $0.01 par value; 500,000,000 shares authorized and 125,972,127 and 125,912,647 shares issued and outstanding, respectively		1,258				1,257
Additional paid-in capital		1,165,097				1,163,939
Accumulated other comprehensive income (loss)		299				(703	)
Accumulated earnings		120,752				124,566
Noncontrolling interests:
Operating partnership		74,534				69,140
Consolidated subsidiaries		19,514				18,273
Total equity		1,381,454				1,376,472
Total liabilities and equity	$	3,388,961			$	3,311,871

URBAN EDGE PROPERTIES
CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except per share amounts)
	Three Months Ended March 31,
	2026				2025
REVENUE
Rental revenue	$	124,185			$	118,092
Other income		8,439				73
Total revenue		132,624				118,165
EXPENSES
Depreciation and amortization		32,312				37,195
Real estate taxes		16,602				16,358
Property operating		28,938				24,059
General and administrative		9,136				9,531
Lease expense		3,173				3,371
Total expenses		90,161				90,514
Interest income		393				607
Interest and debt expense		(18,719	)			(19,755	)
(Loss) gain on extinguishment of debt		(212	)			498
Income before income taxes		23,925				9,001
Income tax expense		(378	)			(619	)
Net income		23,547				8,382
Less net (income) loss attributable to noncontrolling interests in:
Operating partnership		(1,177	)			(432	)
Consolidated subsidiaries		275				248
Net income attributable to common shareholders	$	22,645			$	8,198
Earnings per common share – Basic:	$	0.18			$	0.07
Earnings per common share – Diluted:	$	0.18			$	0.07
Weighted average shares outstanding – Basic		125,879				125,513
Weighted average shares outstanding – Diluted		131,105				125,603

Reconciliation of Net Income to FFO and FFO as Adjusted

The following table reflects the reconciliation of net income to FFO and FFO as Adjusted for the three months ended March 31, 2026 and 2025. Net income is considered the most directly comparable GAAP measure. Refer to “Non-GAAP Financial Measures” on page 6 for a description of FFO and FFO as Adjusted.

	Three Months Ended March 31,
(in thousands, except per share amounts)	2026				2025
Net income	$	23,547			$	8,382
Less net (income) loss attributable to noncontrolling interests in:
Consolidated subsidiaries		275				248
Operating partnership		(1,177	)			(432	)
Net income attributable to common shareholders		22,645				8,198
Adjustments:
Rental property depreciation and amortization		31,835				36,828
Limited partnership interests in operating partnership		1,177				432
FFO Applicable to diluted common shareholders		55,657				45,458
FFO per diluted common share(1)		0.42				0.35
Adjustments to FFO:
Transaction, severance, litigation expenses and other, net(2)		(8,300	)			1,024
Non-cash adjustments(3)		—				(63	)
Loss (gain) on extinguishment of debt		212				(498	)
FFO as Adjusted applicable to diluted common shareholders	$	47,569			$	45,921
FFO as Adjusted per diluted common share(1)	$	0.36			$	0.35
Weighted Average diluted common shares(1)		131,105				130,328

(1)	Weighted average diluted shares used to calculate FFO per share and FFO as Adjusted per share for the three months ended March 31, 2025 are higher than the GAAP weighted average diluted shares as a result of the dilutive impact of LTIP and OP units which may be redeemed for our common shares.
(2)	Includes $8.4 million of non-recurring reimbursements related to environmental remediation costs, and $0.1 million of transaction costs and severance expenses for the three months ended March 31, 2026.
(3)	Includes the acceleration and write-off of lease intangibles related to tenant bankruptcies.

Reconciliation of Net Income to NOI and Same-Property NOI

The following table reflects the reconciliation of net income to NOI, same-property NOI and same-property NOI including properties in redevelopment for the three months ended March 31, 2026 and 2025. Net income is considered the most directly comparable GAAP measure. Refer to “Non-GAAP Financial Measures” on page 6 for a description of NOI and same-property NOI.

	Three Months Ended March 31,
(in thousands)	2026				2025
Net income	$	23,547			$	8,382
Depreciation and amortization		32,312				37,195
Interest and debt expense		18,719				19,755
General and administrative expense		9,136				9,531
Loss (gain) on extinguishment of debt		212				(498	)
Other (income) expense		(8,066	)			467
Income tax expense		378				619
Interest income		(393	)			(607	)
Non-cash revenue and expenses		(2,819	)			(3,272	)
NOI		73,026				71,572
Adjustments:
Sunrise Mall net operating loss		479				295
Tenant bankruptcy settlement income and lease termination income		—				(61	)
Non-same property NOI and other(1)		(8,246	)			(8,091	)
Same-property NOI	$	65,259			$	63,715
NOI related to properties being redeveloped		6,583				6,149
Same-property NOI including properties in redevelopment	$	71,842			$	69,864

(1)	Non-same property NOI includes NOI related to properties being redeveloped and properties acquired, disposed, or that are in the foreclosure process during the periods being compared, and results of the Company’s captive insurance program.

Reconciliation of Net Income to EBITDAre and Adjusted EBITDAre

The following table reflects the reconciliation of net income to EBITDAre and Adjusted EBITDAre for the three months ended March 31, 2026 and 2025. Net income is considered the most directly comparable GAAP measure. Refer to “Non-GAAP Financial Measures” on page 6 for a description of EBITDAre and Adjusted EBITDAre.

	Three Months Ended March 31,
(in thousands)	2026				2025
Net income	$	23,547			$	8,382
Depreciation and amortization		32,312				37,195
Interest and debt expense		18,719				19,755
Income tax expense		378				619
EBITDAre		74,956				65,951
Adjustments for Adjusted EBITDAre:
Transaction, severance, litigation expenses and other, net(1)		(8,300	)			1,024
Loss (gain) on extinguishment of debt		212				(498	)
Non-cash adjustments(2)		—				(63	)
Adjusted EBITDAre	$	66,868			$	66,414

(1)	Includes $8.4 million of non-recurring reimbursements related to environmental remediation costs, and $0.1 million of transaction costs and severance expenses for the three months ended March 31, 2026.
(2)	Includes the acceleration and write-off of lease intangibles related to tenant bankruptcies.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260429684004/en/

For additional information:

Mark Langer, EVP and

Chief Financial Officer

212-956-0082

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: REIT Retail Department Stores Commercial Building & Real Estate Construction & Property

MEDIA:

Logo

NIQ Launches Precision Solutions to Transform Localized Growth Strategies

New integrated solution combines AI-enabled analytics with NIQ’s data assets to help brands and retailers drive targeted, measurable growth

CHICAGO–(BUSINESS WIRE)–
NIQ (NYSE: NIQ), a global leader in consumer intelligence, today announced the launch of Precision Solutions in the United States, a new integrated solution designed to help brands and retailers make more precise, localized decisions that drive growth.

As shopper behavior becomes more fragmented and varies significantly by location, many organizations struggle to move beyond broad, market-level strategies. This often leads to inefficient spend, missed opportunities, and difficulty proving return on investment.

Precision Solutions helps solve this by enabling a more targeted, localized approach to growth for brands and retailers.

The solution combines NIQ’s retail measurement data, consumer panel data, and advanced analytics into a single platform that allows organizations to identify where growth is happening, target the right opportunities, test strategies in-market, and measure results with confidence.

“For brands, growth today is no longer about doing more everywhere. It is about taking the right actions in the right places,” said Kim Cox, Managing Director, NIQ. “Precision Solutions gives teams the clarity to see where demand truly exists, the confidence to prioritize the stores that matter most, and the evidence to act decisively. When execution is guided by local precision, performance follows.”

Precision Solutions also brings together previously separate capabilities into a unified experience, simplifying workflows and enabling more consistent, scalable decision-making.

With Precision Solutions, organizations can:

• Identify high-potential stores, geographies, and shopper segments

• Focus investments where they are most likely to drive growth

• Test strategies in-market and measure impact quickly

• Optimize assortment, promotions, and media with greater precision

Built on NIQ’s comprehensive data ecosystem and enhanced with AI-enabled analytics, Precision Solutions allows clients to simulate outcomes, isolate true performance, and scale the strategies that deliver measurable results.

Precision Solutions is now available to clients in the United States. For more information, visit NIQ’s Precision Solutions site or contact your NIQ representative.

FAQS

What is Precision Solutions?

Precision Solutions is an integrated localization and targeting solution from NIQ that helps brands and retailers identify, target, test, and optimize growth opportunities at a local level. It combines retail measurement, consumer data, and advanced analytics into a single platform.

What problem does Precision Solutions solve?

Many organizations rely on broad, market-level strategies that can lead to inefficient spend and missed growth opportunities. Precision Solutions helps clients focus on the most impactful stores, geographies, and shopper segments, improving targeting and ROI.

How is Precision Solutions different from existing NIQ solutions?

Precision Solutions unifies multiple existing capabilities—including Spectra, Precision Areas, and Test & Learn—into one integrated solution, making it easier to move from insight to action and measure results consistently.

Who should use Precision Solutions?

Precision Solutions is designed for brands and retailers, particularly those using NIQ’s retail measurement services, who want to improve targeting, optimize investments, and drive localized growth.

How does Precision Solutions use AI?

Precision Solutions uses AI-enabled analytics to model outcomes, simulate scenarios, and help predict the impact of different strategies. This allows clients to make more informed, data-driven decisions.

What are the key benefits of Precision Solutions?

• More precise targeting of stores, locations, and shoppers

• Supports more effective resource allocation

• Faster testing and validation of strategies

• Ability to scale successful strategies with greater confidence

Is Precision Solutions available globally?

Precision Solutions is currently available in the United States, with expansion plans to be evaluated over time.

About NIQ

NielsenIQ (NYSE: NIQ) is a leading consumer intelligence company, delivering the most complete and trusted understanding of consumer buying behavior and revealing new pathways to growth. By combining an unmatched global data footprint and granular consumer and retail measurement with decades of AI modeling expertise, NIQ builds decision systems that help companies turn complex data into confident action.

With operations in more than 90 countries, NIQ covers approximately 82% of the world’s population and more than $7.4 trillion in global consumer spend. Through cloud-based platforms, advanced analytics and AI-driven insights, NIQ delivers The Full View™—helping brands and retailers understand what consumers buy, why they buy it, and what to do next.

For more information, please visit www.niq.com.

Forward Looking Statement

This press release contains forward-looking statements. These forward-looking statements address various matters including statements about benefits, features, and outcomes of NIQ Precision Solutions and related capabilities and other statements contained in this press release that are not historical facts. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially. Forward-looking statements speak only as of the date made and NIQ undertakes no obligation to update them except as required by law.

© 2026 Nielsen Consumer LLC. All Rights Reserved.

NIQ-General

View source version on businesswire.com: https://www.businesswire.com/news/home/20260429087488/en/

Media Contact:

NIQ North America Communications

[email protected]

KEYWORDS: Illinois United States North America

INDUSTRY KEYWORDS: Technology Retail Consumer Professional Services Artificial Intelligence Other Retail Public Relations/Investor Relations Marketing Software Advertising Data Analytics Other Consumer Communications Content Marketing

MEDIA:

Logo

National Vision Holdings, Inc. Announces First Quarter 2026 Earnings Release and Conference Call

DULUTH, Ga.–(BUSINESS WIRE)–
National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) will report its first quarter 2026 financial results before the market opens on Wednesday, May 13, 2026, and will host a conference call at 8:30 a.m. Eastern Time. To pre-register for the conference call and obtain a dial-in number and passcode, please refer to the “Investors” section of the Company’s website at https://ir.nationalvision.com.

A live audio webcast of the conference call, together with related materials, will be available online in the “Investors” section of the Company’s website. A replay of the audio webcast will be available shortly after the broadcast.

About National Vision Holdings, Inc.

National Vision Holdings, Inc. (NASDAQ: EYE) is one of the largest optical retail companies in the United States with over 1,200 stores in 38 states and Puerto Rico. With a mission of helping people by making quality eye care and eyewear more affordable and accessible, the company operates four retail brands: America’s Best, Eyeglass World, and Vista Opticals inside select Fred Meyer stores and on select military bases, and an e-commerce website DiscountContacts.com, offering a variety of products and services for customers’ eye care needs. For more information, please visit www.nationalvision.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260429419711/en/

Investor Contact:

[email protected]

National Vision Holdings, Inc.

Tamara Gonzalez

ICR, Inc.

Caitlin Churchill

Media Contact:

[email protected]

KEYWORDS: Georgia United States North America

INDUSTRY KEYWORDS: Online Retail Health Retail Optical Specialty

MEDIA:

Posted on April 29, 2026 7:04 am

Amarin Reports 2026 First Quarter Financial Results

Total Revenue Increased Led by Higher International Sales

Generated Positive Cash Flow and Reiterates Expectation for Full Year Positive Cash Flow

Recently Updated Industry Guidelines Expand Global Medical Society Endorsements Supporting the Use of Icosapent Ethyl (IPE) in Contemporary Lipid and Cardiovascular Risk Management

DUBLIN, Ireland and BRIDGEWATER, N.J., April 29, 2026 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the first quarter ended March 31, 2026 (Q1 2026).

“Our results for Q1 2026 reflected the early yet measurable progress generated by our refined global business model which we adopted in mid-2025,” said Aaron Berg, President and Chief Executive Officer.

“The promise of our fully-partnered international commercial strategy – anchored by our European-focused exclusive licensing and supply agreement with Recordati S.p.A. (Recordati) – was reflected in higher European product revenue in Q1 2026 compared to Q4 2025. This consecutive quarterly growth was attributable to strong in-market demand for VAZKEPA^® (icosapent ethyl) and the priority assigned by Recordati to expand the commercial reach for this proven therapy. While acknowledging that European sales will vary quarter to quarter, especially in the early days of this new partnership, these initial results are encouraging. Recordati has commenced commercial efforts of VAZKEPA in 10 countries, including a Q4 2025 launch in Italy, and plans to expand its distribution across Europe over the next several years. We are also seeing good growth from our active commercial partners outside of Europe.”

“Our U.S. franchise continues to demonstrate remarkable resilience, where we have maintained our leading market share for VASCEPA^® more than five years since the introduction of generics. Industry prescription data for Q1 2026 showed an overall increase in the icosapent ethyl (IPE) market while VASCEPA-branded prescriptions rose by 17% compared to Q1 2025. We expect that volumes will remain stable throughout 2026. Our streamlined U.S. operation remains an efficient, cash generating engine for our Company.” 

He continued, “We are encouraged by the 2026 American College of Cardiology (ACC) / American Heart Association (AHA)/Multisociety Dyslipidemia Guideline Update from March of this year that supports the broader clinical role of IPE in reducing cardiovascular (CV) risk in statin-treated patients with elevated triglycerides. These guidelines shift CV care toward early, lifelong prevention and a more comprehensive risk approach beyond just lowering LDL cholesterol. In recognizing that high triglyceride levels contribute to CV events in many patients, this framework underscores the need for additional therapies beyond statins to address this care gap. This evolutionary perspective on CV risk management is timely and strengthens our position to address the burden of CV disease in patients and across the healthcare ecosystem.”

Mr. Berg concluded, “We have created a new version of Amarin – focused, leaner, and both financially and operationally stronger than at any time in our recent history. The growth initiatives we have undertaken and building industry tailwinds increasingly focused on the needs of patients with elevated triglycerides have positioned us well for 2026. Our team is executing with focus and discipline to achieve our objectives and deliver shareholder value, while continuing to work closely with Barclay’s, our exclusive financial advisor, in exploring additional potential pathways to further enhance shareholder value. While there is still work to be done, we look forward to our future with confidence.”   

Q1 2026 Financial Highlights

($ in millions)	Q1 2026		Q1 2025		% Change
Total Net Revenue	$45.1		$42.0		7%
Operating Expenses	$29.1		$41.9		(31)%
Operating Loss Operating Margin % *	$(11.3) (25)%		$(16.8) (40)%		(32)% NM
Net Loss Net Margin	$(10.5) (23)%		$(15.7) (37)%		(33)% NM
Cash	$307.8		$281.8		9%
* Operating margin is calculated as operating loss divided by total net revenue. NM – Not Meaningful

Peter Fishman, Amarin’s Chief Financial Officer, said, “We are encouraged by our Q1 2026 performance under our new business model. We achieved higher total revenue, led by growth from our partners, and a continued decline in our operating expenses, both of which led to significantly narrowed losses compared to the same period last year. We remain on track to realize the approximately $70 million in cost savings and have incurred nearly all of the associated restructuring costs. Finally, we generated positive cash flow for the second consecutive quarter and continue to expect to be cash flow positive for full year 2026.”

Q1 2026 Financial Performance

Comparisons to Q1 2025, unless otherwise stated

Revenues

($ in millions)	Q1 2026		Q1 2025		% Change
Product Revenue, net:               U.S.               Europe               Rest-of-World (ROW)	$35.6 $4.9 $2.8		$35.7 $5.4 $0		(0)% (9)% NM
Total Product Revenue, net	$43.3		$41.0		6%
Licensing & Royalties	$1.8		$1.0		84%
Total Net Revenue	$45.1		$42.0		7%
NM – Not Meaningful

Total Net Revenue: Increased $3.1 million, or 7%. U.S. sales of VASCEPA were consistent with the prior year period, benefitting from an increase in volume related to the regaining of exclusive status with a large national pharmacy benefit manager (PBM) beginning in Q3 2025. A slight decline in European revenue was attributable to moving to a partnered sales model in the second half of 2025, a transition that had yet to take effect in Q1 2025. Quarter-to-quarter European sales comparisons that reflect the partnership model with Recordati will commence in Q3 2026. Licensing and royalty revenue increased by 84% due to higher in-market sales generated by our international commercial sales partners.

Operating Expenses


Comparisons to Q1 2025, unless otherwise stated

($ in millions)	Q1 2026		Q1 2025	% Change
COGS	$27.4		$16.9	62%
SG&A	$21.1		$36.6	(42)%
R&D	$4.7		$5.3	(12)%
Restructuring	$3.3		—	NM
Total Operating Expenses *	$29.1		$41.9	(31)%
* Total operating expenses reflect the sum of SG&A, R&D, and Restructuring expenses. NM – Not Meaningful

Total Operating Expenses: Decreased $12.8 million, or 31%, primarily due to the impact of the June 2025 Global Restructuring that produced declines in Selling, General, and Administrative expenses (SG&A). Excluding the restructuring charge of $3.3 million (see discussion below), Q1 2026 total operating expenses were $25.8 million, representing a decline of 38%.

COGS: Increased $10.5 million, or 62%, reflecting increased product volumes to satisfy demand associated with our exclusive PBM relationship that took effect July 1, 2025 and shipments to ROW partners that did not exist in last year’s first quarter.

SG&A: Decreased $15.5 million, or 42%, primarily due to a reduction in costs pursuant to the Global Restructuring and other cost optimization initiatives, slightly offset by litigation settlements.

R&D: Consistent with the prior year period.

Restructuring: The Company recognized $3.3 million in Q1 2026 related to the continued implementation of the Global Restructuring associated with the execution of the Recordati Licensing Agreement announced in June 2025. The Company has incurred a total of $ 39.6 million of restructuring charges through Q1 2026, with the remaining nominal charges expected to be realized in Q2 2026.

Additional Q1 2026 Financial Information


Comparisons to Q1 2025, unless otherwise stated

Operating Loss: Narrowed to $11.3 million from an operating loss of $16.8 million, an improvement of $5.4 million, or 32%. Operating loss in Q1 2026 included restructuring costs of $3.3 million compared to no such charges in Q1 2025.

Net Loss: Improved to $10.5 million, or $(0.03) per share, from a net loss of $15.7 million, or $(0.04) per share.

Cash: Reported aggregate cash and investments rose to $307.8 million as of March 31, 2026 compared to $302.6 million as of December 31, 2025.

Debt: Remained debt free as of March 31, 2026.

First Quarter 2026 Earnings Conference Call and Webcast Information

Amarin will host a conference call on April 29, 2026, at 8:00 a.m. ET to discuss this information. The conference call can be accessed on the investor relations section of the Company’s website at www.amarincorp.com, or via telephone by dialing 888-506-0062 within the United States, 973-528-0011 from outside the United States, and referencing conference ID 543818. A replay of the webcast will be made available until October 29, 2026. To listen to a replay of the call, dial 877-481-4010 from within the United States and 919-882-2331 from outside of the United States, and reference conference ID 53836. A replay of the call will also be available through the Company’s website shortly after the call. 

About Amarin
Amarin is a global pharmaceutical company committed to reducing the cardiovascular disease (CVD) burden for patients and communities and to advancing the science of cardiovascular care around the world. We own and support a global branded product approved by multiple regulatory authorities based on a track record of proven efficacy and safety and backed by robust clinical trial evidence. Our commercialization model includes a direct sales approach in the U.S. and an indirect distribution strategy internationally, through a syndicate of reputable and well-established partners with significant geographic expertise, covering close to 100 markets worldwide. Our success is driven by a dedicated, talented, and highly skilled team of experts passionate about the fight against the world’s leading cause of death, CVD.

About VASCEPA^®/VAZKEPA^® (icosapent ethyl) Capsules

VASCEPA (icosapent ethyl) capsules are the first prescription treatment approved by the U.S. Food and Drug Administration (FDA) comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. VASCEPA was launched in the United States in January 2020 as the first drug approved by the U.S. FDA for treatment of the studied high-risk patients with persistent cardiovascular risk despite being on statin therapy. VASCEPA was initially launched in the United States in 2013 based on the drug’s initial FDA approved indication for use as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Since launch, VASCEPA has been prescribed more than twenty-five million times. VASCEPA is covered by most major medical insurance plans. In addition to the United States, VASCEPA is approved and sold in Canada, China, Australia, Lebanon, the United Arab Emirates, Saudi Arabia, Qatar, Bahrain, and Kuwait. In Europe, in March 2021 marketing authorization was granted to icosapent ethyl in the European Union for the reduction of risk of cardiovascular events in patients at high cardiovascular risk, under the brand name VAZKEPA. In April 2021 marketing authorization for VAZKEPA (icosapent ethyl) was granted in the United Kingdom (applying to England, Scotland, Wales, and Northern Ireland). VAZKEPA (icosapent ethyl) is currently approved and sold in Europe in Sweden, Finland, England/Wales, Spain, Netherlands, Scotland, Greece, Portugal, Italy, Denmark and Austria.

United States Indications and Limitation of Use

VASCEPA is indicated:  

• As an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and established cardiovascular disease or diabetes mellitus and two or more additional risk factors for cardiovascular disease.  
• As an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. 

The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined. 

Important Safety Information

• VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components.
• VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter. 
• It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur. 
• VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin. 
• Common adverse reactions in the cardiovascular outcomes trial (incidence ≥3% and ≥1% more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%), and atrial fibrillation (5% vs 4%). 
• Common adverse reactions in the hypertriglyceridemia trials (incidence >1% more frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%). 
• Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088. 
• Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for bleeding.

FULL U.S. FDA-APPROVED VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT 

WWW.VASCEPA.COM

Europe

 

For further information about the Summary of Product Characteristics (SmPC) for VAZKEPA^® in Europe, please visit:  https://www.ema.europa.eu/en/documents/product-information/vazkepa-epar-product-information_en.pdf

Globally, prescribing information varies; refer to the individual country product label for complete information.

Use of Non-GAAP Adjusted Financial Information

Included in this press release are non-GAAP adjusted financial information as defined by U.S. Securities and Exchange Commission Regulation G. The GAAP financial measure is most directly comparable to each non-GAAP adjusted financial measure used or discussed, and a reconciliation of the differences between each non-GAAP adjusted financial measure and the comparable GAAP financial measure, is included in this press release after the condensed consolidated financial statements.

Non-GAAP adjusted net (loss) income was derived by taking GAAP net loss and adjusting it for non-cash stock-based compensation expense, restructuring expense and other one-time expenses. Management uses these non-GAAP adjusted financial measures for internal reporting and forecasting purposes, when publicly providing its business outlook, to evaluate the company’s performance and to evaluate and compensate the company’s executives. The company has provided these non-GAAP financial measures in addition to GAAP financial results because it believes that these non-GAAP adjusted financial measures provide investors with a better understanding of the company’s historical results from its core business operations.

While management believes that these non-GAAP adjusted financial measures provide useful supplemental information to investors regarding the underlying performance of the company’s business operations, investors are reminded to consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. Non-GAAP measures have limitations in that they do not reflect all the amounts associated with the company’s results of operations as determined in accordance with GAAP. In addition, it should be noted that these non-GAAP financial measures may be different from non-GAAP measures used by other companies, and management may utilize other measures to illustrate performance in the future.

Forward-Looking Statements

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including beliefs about Amarin’s key achievements in 2025 and the potential impact and outlook for achievements in 2026 and beyond; Amarin’s 2026 financial outlook and cash position; Amarin’s overall efforts to expand access and reimbursement to VAZKEPA across global markets; expectations regarding potential strategic collaboration and licensing agreements with third parties, including our ability to attract additional collaborators, as well as our plans and strategies for entering into potential strategic collaboration and licensing agreements and the overall potential and future success of VASCEPA/VAZKEPA and Amarin that are based on the beliefs and assumptions and information currently available to Amarin.

All statements other than statements of historical fact contained in this press release are forward-looking statements. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin’s filings with the U.S. Securities and Exchange Commission, including Amarin’s quarterly report on Form 10-Q for the period ending March 31, 2026 and annual report on Form 10-K for the fiscal year ended 2025. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Amarin undertakes no obligation to update or revise the information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. Amarin’s forward-looking statements do not reflect the potential impact of significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that Amarin may enter into, amend or terminate. Investors and others should note that Amarin communicates with its investors and the public using the company website (www.amarincorp.com), the investor relations website (www.amarincorp.com/investor-relations), including but not limited to investor presentations and investor FAQs, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts.

Amarin Contact Information
Media Inquiries:
Tegan Berry
Amarin Corporation plc
[email protected]

Investor Inquiries:
Devin Sullivan & Conor Rodriguez
The Equity Group on Behalf of Amarin
[email protected] or [email protected]
[email protected]

-Tables to Follow-

CONSOLIDATED BALANCE SHEET DATA
(U.S. GAAP)
Unaudited
		March 31, 2026				December 31, 2025
		(in thousands)
ASSETS
Current Assets:
Cash and cash equivalents		$	131,063			$	134,660
Restricted cash			201				201
Short-term investments			176,759				167,929
Accounts receivable, net			108,051				126,832
Inventory			183,585				195,910
Prepaid and other current assets			26,357				24,350
Total current assets			626,016				649,882
Operating lease right-of-use asset			6,010				6,461
Other long-term assets			1,010				1,067
Intangible asset, net			12,728				13,365
TOTAL ASSETS		$	645,764			$	670,775
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable		$	48,153			$	45,355
Accrued expenses and other current liabilities			131,491				149,104
Total current liabilities			179,644				194,459
Long-Term Liabilities:
Long-term operating lease liability			5,585				6,080
Other long-term liabilities			11,122				10,955
Total liabilities			196,351				211,494
Stockholders’ Equity:
Common stock			314,062				310,184
Additional paid-in capital			1,922,254				1,923,801
Treasury stock			(69,047	)			(67,360	)
Accumulated deficit			(1,717,856	)			(1,707,344	)
Total stockholders’ equity			449,413				459,281
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY		$	645,764			$	670,775

CONSOLIDATED STATEMENTS OF OPERATIONS DATA
(U.S. GAAP)
Unaudited
		Three months ended March 31,
		(in thousands, except per share amounts)
			2026				2025
Product revenue, net		$	43,326			$	41,035
Licensing and royalty revenue			1,806				982
Total revenue, net			45,132				42,017
Less: Cost of goods sold			27,363				16,887
Gross margin			17,769				25,130
Operating expenses:
Selling, general and administrative (1)			21,115				36,573
Research and development (1)			4,665				5,312
Restructuring			3,323				—
Total operating expenses			29,103				41,885
Operating loss			(11,334	)			(16,755	)
Interest income, net			2,423				2,872
Other income, net			188				253
Loss from operations before taxes			(8,723	)			(13,630	)
Provision for income taxes			(1,789	)			(2,067	)
Net loss		$	(10,512	)		$	(15,697	)
Loss per Ordinary Share:
Basic		$	(0.03	)		$	(0.04	)
Diluted		$	(0.03	)		$	(0.04	)
Weighted average Ordinary Shares:
Basic			419,054				413,422
Diluted			419,054				413,422
(1) – Excluding non-cash stock-based compensation, selling, general and administrative expenses were $19,385 and $33,045 for the three months ended March 31, 2026 and 2025, respectively, and research and development expenses were $4,100 and $4,513, respectively, for the same periods.

RECONCILIATION OF NON-GAAP NET INCOME (LOSS)
Unaudited
		Three months ended March 31,
		(in thousands, except per share amounts)
			2026				2025
Net loss for EPS1– GAAP			(10,512	)			(15,697	)
Stock-based compensation expense			2,296				4,327
Restructuring			3,323				—
Litigation Settlement			3,100				—
ADS Ratio Change Fees			—				2,015
Net loss for EPS1– non-GAAP		$	(1,793	)		$	(9,355	)
1basic and diluted
Loss per Ordinary Share:
Basic – non-GAAP		$	(0.00	)		$	(0.02	)
Diluted – non-GAAP		$	(0.00	)		$	(0.02	)
Loss per ADS:
Basic – non-GAAP		$	(0.09	)		$	(0.45	)
Diluted – non-GAAP		$	(0.09	)		$	(0.45	)
Weighted average Ordinary Shares:
Basic			419,054				413,422
Diluted			419,054				413,422